Perspectives on Enquiry & Evidence

Hello! I’m delighted to pen my inaugural blog post here as Cytel’s Chief Medical Officer. In this series, we’ll explore..

For over a decade, the number one reason cited for trial discontinuity has been challenges associated with recruitment..

Cytel blogs bring you debate and discussion of the newest trends in statistics and quantitative strategy. In 2021, our..

Sponsors bringing a successful new product to market have to overcome two hurdles: submission and reimbursement. For..

Traditionally, the teams responsible for clinical development and regulatory submissions do not consult the market..

There are many reasons why traditional approaches to designing a clinical study are generally suboptimal and do not..

A good clinical study design performs well not only under the ideal target scenario. Statisticians should be able to..

A staged investment strategy aligns R&D decisions and financial planning with the interim looks of a clinical trial. If..

For health innovators, trial selection is a key success factor as there are no second chances. But how do you find the..